Iori A P, Screnci M, Guglielmi C, Mengarelli A, Carmini D, Testi A M, Moleti M L, Cimino G, Perrone P, Laurenti L, Elia L, Boecklin F, Romano A, Vulcano F, De Felice L, Arcese W
Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy.
Bone Marrow Transplant. 1998 Jul;22 Suppl 1:S75.
Ten consecutive children with high risk leukemia have been submitted to UCB transplant from unrelated HLA mismatched donors. All patients received an identical regimen for conditioning and GVHD prophylaxis. The median dose of viable nucleated cells infused was 2.6 x 10(6)/kg b.w. Among the nine patients evaluable for engraftment the hematopoiesis was of full donor origin in six patients and autologous in three. At a median follow-up of 9 months, six of nine (67%) patients are alive in CR.
十名患有高危白血病的连续儿童接受了来自无关HLA不匹配供体的脐血移植。所有患者接受相同的预处理和移植物抗宿主病预防方案。输注的有活力有核细胞的中位剂量为2.6×10(6)/kg体重。在可评估植入情况的九名患者中，六名患者的造血完全来自供体，三名患者为自体造血。在中位随访9个月时，九名患者中有六名（67%）在完全缓解中存活。
